Issue link: https://viewer.e-digitaledition.com/i/1177726
Penn State Health Tests Novel, Nonsurgical Therapy for Common Form of Bladder Cancer BY THOMAS CROCKER PATIENTS WITH A NONINVA SIVE, LOW-GR ADE FORM OF BL ADDER CANCER OF TEN NEED MULTIPLE SURGERIES TO TRE AT RECURRENCES, WHICH ARE COMMON. A NE W CHEMOABL ATIVE GEL CURRENTLY UNDER STUDY AT PENN STATE HE ALTH MAY ELIMINATE THE NEED FOR THOSE PROCEDURES. PENN STATE HE ALTH is one of 25 centers in the United States pa r ticipating in a phase 2, single-a rm clinica l tria l of UGN-102 — a gel form of the chemotherapy dr ug mitomycin C, which is w idely used to prevent t u mors f rom recu r r i n g — a s a pr i ma r y t reat ment for individua ls with low-g rade non-muscle-invasive bladder ca ncer (NMIBC) w ith intermediate risk of recurrence. UGN-102 enters the bladder a s a liquid via catheter, but once inside, it gelatinizes a nd coats the bladder wa ll to ablate tumors. A f ter six hours, the drug liquef ies a nd patients void it through the urine. " Instead of on ly preventing tumors from return- ing, UGN-102 a llows us to treat them," says Penn State Hea lth Professor and Chief of Urolog y Jay Raman, MD, FACS, who is managing the study at Penn State Hea lth. "It releases a higher tissue concentration of mitomycin C, which ablates the prima r y tumor a nd a lso treats unseen a rea s i n t he bladder t hat may ha rbor microscopic disease. Mitomycin C has been on the ma rket for yea rs, a nd we use it in st a nda rd pra ctice to prevent bla dder t u m o r s f r o m r e c u r r i n g f o l l o w i n g surger y. UGN-102 builds on current sta nda rds of ca re. We're usi ng a n existing dr ug but delivering it in a new, noninvasive way." 0 6❱❱❱❱❱ A D V A N C E D C L I N I C A L T R I A L S

